miR-1285-3p Controls Colorectal Cancer Proliferation and Escape from Apoptosis through DAPK2.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
31 Mar 2020
Historique:
received: 29 01 2020
revised: 23 03 2020
accepted: 29 03 2020
entrez: 5 4 2020
pubmed: 5 4 2020
medline: 8 1 2021
Statut: epublish

Résumé

MicroRNAs are tiny but powerful regulators of gene expression at the post-transcriptional level. Aberrant expression of oncogenic and tumor-suppressor microRNAs has been recognized as a common feature of human cancers. Colorectal cancer represents a major clinical challenge in the developed world and the design of innovative therapeutic approaches relies on the identification of novel biological targets. Here, we perform a functional screening in colorectal cancer cells using a library of locked nucleic acid (LNA)-modified anti-miRs in order to unveil putative oncogenic microRNAs whose inhibition yields a cytotoxic effect. We identify miR-1285-3p and further explore the effect of its targeting in both commercial cell lines and primary colorectal cancer stem cells, finding induction of cell cycle arrest and apoptosis. We show that DAPK2, a known tumor-suppressor, is a novel miR-1285 target and mediates both the anti-proliferative and the pro-apoptotic effects of miR-1285 depletion. Altogether, our findings uncover a novel oncogenic microRNA in colorectal cancer and lay the foundation for further studies aiming at the development of possible therapeutic strategies based on miR-1285 targeting.

Identifiants

pubmed: 32244500
pii: ijms21072423
doi: 10.3390/ijms21072423
pmc: PMC7177834
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
MIRN1285 microRNA, human 0
MicroRNAs 0
Oligonucleotides 0
locked nucleic acid 0
DAPK2 protein, human EC 2.7.11.1
Death-Associated Protein Kinases EC 2.7.11.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : Investigator Grant 13431

Déclaration de conflit d'intérêts

Supplementary Materials: The following are available online at www.mdpi.com/1422-0067/21/7/2423/s1.

Références

Oncogene. 2011 Mar 24;30(12):1481-8
pubmed: 21102518
Cell Death Differ. 2014 May;21(5):774-82
pubmed: 24488097
Mol Cell Biol. 2015 Oct 19;36(1):132-43
pubmed: 26483415
Mol Cell Biol. 2000 Feb;20(3):1044-54
pubmed: 10629061
Cancer Cell. 2014 Apr 14;25(4):469-83
pubmed: 24735923
Nat Commun. 2018 May 1;9(1):1759
pubmed: 29717115
Autophagy. 2016 Dec;12(12):2271-2285
pubmed: 27653365
N Engl J Med. 2013 May 2;368(18):1685-94
pubmed: 23534542
Apoptosis. 2014 Feb;19(2):286-97
pubmed: 24220854
J Biol Chem. 2009 Jan 23;284(4):2012-22
pubmed: 18957423
Curr Opin Pharmacol. 2017 Aug;35:1-11
pubmed: 28527911
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
N Engl J Med. 2008 Oct 23;359(17):1757-65
pubmed: 18946061
Int J Mol Sci. 2017 Mar 15;18(3):
pubmed: 28294974
Nucleic Acids Res. 2017 Sep 29;45(17):10206-10217
pubmed: 28973454
Cell Stem Cell. 2014 Dec 4;15(6):692-705
pubmed: 25479747
Int J Mol Sci. 2018 Mar 23;19(4):
pubmed: 29570632
Nat Rev Drug Discov. 2017 Mar;16(3):203-222
pubmed: 28209991
Oncotarget. 2016 May 3;7(18):26516-34
pubmed: 27049921
Cancer Biomark. 2019;25(1):1-10
pubmed: 31006663
Nature. 2007 Jan 4;445(7123):111-5
pubmed: 17122771
Oncogene. 2016 Mar 3;35(9):1134-42
pubmed: 25982274
Cell Death Dis. 2018 Jan 19;9(2):49
pubmed: 29352138
Cell Rep. 2014 Aug 7;8(3):909-21
pubmed: 25066129
Oncogene. 2008 Sep 25;27(43):5706-16
pubmed: 18521079
Biochem Biophys Res Commun. 2015 Dec 4-11;468(1-2):113-8
pubmed: 26529546
Oncogene. 1999 Jun 10;18(23):3471-80
pubmed: 10376525
J Leukoc Biol. 2007 Jun;81(6):1599-608
pubmed: 17347302
Cell Death Differ. 2015 Mar;22(3):465-75
pubmed: 25361081
EMBO J. 2001 Mar 1;20(5):1099-113
pubmed: 11230133
Nat Genet. 2003 Jul;34(3):267-73
pubmed: 12808457
Adv Nutr. 2016 Mar 15;7(2):418-9
pubmed: 26980827
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Clin Cancer Res. 2013 Apr 15;19(8):2096-106
pubmed: 23446999
Nature. 2005 Jun 9;435(7043):834-8
pubmed: 15944708
J Clin Invest. 2016 Dec 1;126(12):4585-4602
pubmed: 27820701
Tumour Biol. 2015 Jan;36(1):219-25
pubmed: 25230788
Science. 2010 Jan 8;327(5962):198-201
pubmed: 19965718
Cell Death Dis. 2017 Jul 13;8(7):e2929
pubmed: 28703801
Nature. 2004 Sep 16;431(7006):350-5
pubmed: 15372042
Cell. 2000 Jan 7;100(1):57-70
pubmed: 10647931
Dis Model Mech. 2017 Mar 1;10(3):197-214
pubmed: 28250048
J Leukoc Biol. 2014 Jan;95(1):83-93
pubmed: 24038216

Auteurs

Lidia Villanova (L)

Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, 00161 Rome, Italy.

Chiara Barbini (C)

Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, 00161 Rome, Italy.

Cristina Piccolo (C)

Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, 00161 Rome, Italy.

Alessandra Boe (A)

Core Facilities, Istituto Superiore di Sanità, 00161 Rome, Italy.

Ruggero De Maria (R)

Institute of General Pathology, Catholic University of the Sacred Heart and Gemelli Polyclinic, 00168 Rome, Italy.

Micol Eleonora Fiori (ME)

Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, 00161 Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH